Home » Stocks » Moderna

Moderna, Inc. (MRNA)

Stock Price: $69.41 USD -0.83 (-1.18%)
Updated Oct 27, 2020 10:52 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 27.39B
Revenue (ttm) 105.84M
Net Income (ttm) -487.25M
Shares Out 394.59M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE 20.16
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $69.41
Previous Close $70.24
Change ($) -0.83
Change (%) -1.18%
Day's Open 70.45
Day's Range 68.81 - 71.35
Day's Volume 1,390,197
52-Week Range 15.52 - 95.21

More Stats

Market Cap 27.39B
Enterprise Value 24.84B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 394.59M
Float 322.40M
EPS (basic) -1.39
EPS (diluted) -1.39
FCF / Share -0.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 28.22M
Short Ratio 3.02
Short % of Float 8.75%
Beta n/a
PE Ratio n/a
Forward PE 20.16
P/FCF Ratio n/a
PS Ratio 258.77
PB Ratio 9.44
Revenue 105.84M
Operating Income -512.94M
Net Income -487.25M
Free Cash Flow -371.12M
Net Cash 2.55B
Net Cash / Share 6.46
Gross Margin -412.03%
Operating Margin -484.63%
Profit Margin -460.40%
FCF Margin -350.63%
ROA -12.41%
ROE -22.75%
ROIC -32.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (15)

Buy 12
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$92.29*
(32.96% upside)
Low
41.0
Current: $69.41
High
136.0
Target: 92.29
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue60.21135206108
Revenue Growth-55.42%-34.38%89.88%-
Gross Profit60.21135206108
Operating Income-546-413-269-224
Net Income-514-385-256-216
Shares Outstanding33181.1164.5060.75
Earnings Per Share-1.55-4.95-4.18-3.79
Operating Cash Flow-459-331-33166.73
Capital Expenditures-31.55-106-58.40-33.14
Free Cash Flow-491-437-39033.59
Cash & Equivalents1,1041,5227571,058
Total Debt13233.4915.6912.50
Net Cash / Debt9721,4897411,046
Assets1,5891,9621,0841,417
Liabilities415432459575
Book Value1,1751,530-551-335
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Moderna, Inc.
Country United States
Employees 975
CEO Stéphane Bancel

Stock Information

Ticker Symbol MRNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRNA
IPO Date December 7, 2018

Description

Moderna, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.